Nanoparticle Breakthrough Offers Simpler Approach to Cancer and Autoimmune Disease Treatment

Scientists at Johns Hopkins Medicine have engineered biodegradable nanoparticles capable of “educating” the immune system to target and destroy diseased cells throughout the body, offering a potentially simpler and more accessible alternative to current cell-based immunotherapies like CAR-T cell therapy. This research, published in Science Advances, represents a significant step forward in treating cancers and autoimmune diseases such as lupus.

The Limitations of Current Immunotherapies

CAR-T cell therapy, while effective against certain blood cancers, is a complex and expensive process. It requires extracting a patient’s T cells, genetically modifying them to recognize and attack cancer cells, and then reinfusing them back into the patient. This individualized approach is time-consuming and financially burdensome, limiting its widespread availability.

How the Nanoparticles Work

The newly developed nanoparticles are designed to stimulate disease-fighting T cells, prompting them to seek out and destroy B cells – the immune cells responsible for producing antibodies that contribute to autoimmune diseases like lupus and certain blood cancers, including leukemia and lymphoma .

These nanoparticles are constructed from polymers that break down in water and are decorated with anti-CD3 and anti-CD28 antibody molecules. These antibodies support the nanoparticles locate and activate T cells. Unlike some other nanoparticle designs that require five components, the Johns Hopkins nanoparticles utilize a simpler three-component structure .

The nanoparticles also carry mRNA, genetic instructions that tell T cells to express receptors capable of identifying and attacking the problematic B cells.

Promising Results in Mouse Models

In experiments conducted on mice, a single dose of the nanoparticles resulted in the depletion of 95% of target B cells in the bloodstream within 24 hours. Approximately 50% of B cells were also eliminated from the spleen . After one week, the B cell population in the blood began to recover, reaching about 50% of its original level.

Advantages of the Nanoparticle Approach

• Scalability: The nanoparticle manufacturing process is potentially scalable, making it more accessible than current CAR-T therapies.
• Cost-Effectiveness: The simpler design and manufacturing process could significantly reduce treatment costs.
• Gradual Activation: The nanoparticles activate the immune system in a staged manner, similar to the process of a rocket launching into space .
• Efficient Delivery: The nanoparticles demonstrate a higher success rate in delivering their genetic cargo to cells compared to other nanoparticle technologies, with approximately 10% escaping degradation compartments, compared to 1-2% for other nanoparticles .

Future Directions

Researchers are continuing to refine the nanoparticles to improve their targeting of diseased B cells and optimize the level of T cell stimulation. A recent grant of over $40 million from the Advanced Health Research Projects Agency (ARPA-H) will support further development of these cell engineering tools in collaboration with the biotechnology company ImmunoVec . This research is supported by the Johns Hopkins Translational Immunoengineering Center, a National Center for Biomedical Imaging, and Bioengineering.